The overarching goal of our research is to devise novel antitumour immunotherapeutic modalities that can cure cancer. We have developed a series of human cell-based artificial antigen-presenting cells (APC) that can generate in vitro large numbers of HLA class I-restricted CD8 T cells, class II-restricted CD4 T cells, polyclonal CD3 T cells and CD1d-restricted iNKT cells. Using these artificial APC, we are conducting basic, translational, and clinical research in human T cell immunology. We are particularly interested in understanding how the interactions between T cells and APC affect priming, expansion, persistence and differentiation of T cells. We also seek to clarify how this leads to the subsequent generation and maintenance of T cell memory. Aspiring researchers and trainees who are eager to conquer cancer by harnessing the power of immunity are welcome to our laboratory.
J Autoimmun. 2018 Oct 11;:
Infusion of ex-vivo expanded human TCR-αβ+ double-negative regulatory T cells delays onset of xenogeneic graft-versus-host disease.
Clin Exp Immunol. 2018 Jul 31;:
Clin Cancer Res. 2018 Jun 25;:
DOT1L inhibition attenuates graft-versus-host disease by allogeneic T cells in adoptive immunotherapy models.
Nat Commun. 2018 May 15;9(1):1915
Mechanisms underlying the lack of endogenous processing and CLIP-mediated binding of the invariant chain by HLA-DP84Gly.
Sci Rep. 2018 Mar 19;8(1):4804
A novel chimeric antigen receptor containing a JAK-STAT signaling domain mediates superior antitumor effects.
Nat Med. 2018 Mar;24(3):352-359
MHC class I loaded ligands from breast cancer cell lines: A potential HLA-I-typed antigen collection.
J Proteomics. 2018 Mar 30;176:13-23
J Immunol. 2018 Jan 15;200(2):500-511
Sci Immunol. 2017 Apr 21;2(10):
HLA-DP84Gly constitutively presents endogenous peptides generated by the class I antigen processing pathway.
Nat Commun. 2017 May 10;8:15244
Senior Scientist, Princess Margaret Cancer Centre
Associate Director for Research, Tumor Immunotherapy Program, Princess Margaret Cancer Centre
Professor, Department of Immunology, University of Toronto
Clinician Scientist, Ontario Institute for Cancer Research